April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA83
Academic Journal
Non-alcoholic steatohepatitis (NASH) is an increasingly recognised clinical problem with few if any accepted treatments. Hepatic iron may be a cofactor for hepatic fibrosis in NASH. Aims of this study is to assess the effect of iron depletion by venesection treatment on liver function tests, liver histology, and patient wellbeing in NASH. The study concludes that venesection therapy is a promising treatment for a subgroup of NASH patients.


Related Articles

  • Implication of tumor necrosis factor alpha receptor 1 and hexosaminidase: relationship to pathogenesis of liver diseases. Idriss, N.; Sayyed, Hayam; Zakhary, M.; Sayed, Sherif // Comparative Clinical Pathology;Jul2014, Vol. 23 Issue 4, p1095 

    Liver disease is the main cause of morbidity and mortality worldwide. The spectrum of the disease ranged from fatty liver to hepatic inflammation, necrosis, progressive fibrosis, and hepatocellular carcinoma. We evaluated the serum levels of soluble tumor necrosis factor alpha receptor 1, total...

  • Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. Karlas, Thomas; Petroff, David; Garnov, Nikita; Böhm, Stephan; Tenckhoff, Hannelore; Wittekind, Christian; Wiese, Manfred; Schiefke, Ingolf; Linder, Nicolas; Schaudinn, Alexander; Busse, Harald; Kahn, Thomas; Mössner, Joachim; Berg, Thomas; Tröltzsch, Michael; Keim, Volker; Wiegand, Johannes // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Introduction: Non-invasive assessment of steatosis and fibrosis is of growing relevance in non-alcoholic fatty liver disease (NAFLD). 1H-Magnetic resonance spectroscopy (1H-MRS) and the ultrasound-based controlled attenuation parameter (CAP) correlate with biopsy proven steatosis, but have not...

  • Physiologically Realistic and Validated Mathematical Liver Model Revels Hepatobiliary Transfer Rates for Gd-EOB-DTPA Using Human DCE-MRI Data. Forsgren, Mikael Fredrik; Leinhard, Olof Dahlqvist; Dahlström, Nils; Cedersund, Gunnar; Lundberg, Peter // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Objectives: Diffuse liver disease (DLD), such as non-alcoholic fatty liver disease (NASH) and cirrhosis, is a rapidly growing problem throughout the Westernized world. Magnetic resonance imaging (MRI), based on uptake of the hepatocyte-specific contrast agent (CA) Gd-EOB-DTPA, is a promising...

  • Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers. Poynard, Thierry; Ingiliz, Patrick; Elkrief, Laure; Munteanu, Mona; Lebray, Pascal; Morra, Rachel; Messous, Djamila; Bismut, Francoise Imbert; Roulot, Dominique; Benhamou, Yves; Thabut, Dominique; Ratziu, Vlad // PLoS ONE;2008, Vol. 3 Issue 12, p1 

    Background: Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold standard. Non-invasive techniques, liver stiffness measurements (LSM) and biomarkers [FibroTestH (FT)], are widely used in countries where they are available. The aim was to identify factors associated...

  • Diagnosing Fatty Liver Disease: A Comparative Evaluation of Metabolic Markers, Phenotypes, Genotypes and Established Biomarkers. Siegert, Sabine; Yu, Zhonghao; Wang-Sattler, Rui; Illig, Thomas; Adamski, Jerzy; Hampe, Jochen; Nikolaus, Susanna; Schreiber, Stefan; Krawczak, Michael; Nothnagel, Michael; Nöthlings, Ute // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background:To date, liver biopsy is the only means of reliable diagnosis for fatty liver disease (FLD). Owing to the inevitable biopsy-associated health risks, however, the development of valid noninvasive diagnostic tools for FLD is well warranted. Aim:We evaluated a particular metabolic...

  • In Search of an Ideal Biomarker for Nonalcoholic Fatty Liver Disease. Bambha, Kiran; Yee, Jr., Hal F. // American Journal of Gastroenterology;Jun2008, Vol. 103 Issue 6, p1380 

    The article presents the authors' comments on whether an ideal biomarker exists for the progression of nonalcoholic fatty liver disease (NAFLD) in humans. They state that an ideal biomarker should have the characteristics including, it should be minimally invasive, it should allow repetitive...

  • Non-alcoholic fatty liver disease: what's new under the microscope? Brunt, Elizabeth M. // Gut;Aug2011, Vol. 60 Issue 8, p1152 

    Pathologist's observations have remained central to the evolution of the field of non-alcoholic fatty liver disease, even with the advent of increasingly effective non-invasive markers of advanced fibrosis. As the field matures, the role of pathology has also shifted from being largely...

  • Is transient elastography a useful tool for screening liver disease? Del Poggio, Paolo; Colombo, Silvia; Castellote, Jose // World Journal of Gastroenterology;3/28/2009, Vol. 15 Issue 12, p1409 

    Transient elastography (TE) is a new non invasive tool for measuring liver stiffness, which is correlated to the histologic stage of liver fibrosis. Several studies in chronic liver disease (CLD) have determined a good accuracy of TE in predicting significant fibrosis and an optimal accuracy in...

  • Non-alcoholic steatohepatitis: an overview including treatments with herbals as alternative therapeutics. Thounaojam, Menaka Chanu; Jadeja, Ravirajsinh Navalsinh; Devkar, Ranjisinh Vijaysinh; Ramachandran, Ayalur Vadathala // Journal of Applied Biomedicine (De Gruyter Open);Sep2012, Vol. 10 Issue 3, p119 

    Non-alcoholic steatohepatitis (NASH), an under- recognized hepatic ailment with increasing prevalence, is fast emerging as the dark horse of hepatic related morbidity and mortality. Though introduced as a hepatic condition as early as 1980, detailed exploration of its causes, underlying...


Read the Article


Sign out of this library

Other Topics